Li Yizheng, Liao Weihua, Sun Lunquan
Cancer Center, Xiangya Hospital, Central South University, Hunan Key Laboratory of Molecular Radiation Oncology, International Cooperation Base in Science and Technology for Cancer Precision Medicine, National Clinical Research Center for Geriatric Disorders, Changsha 410008.
Department of Radiology, Xiangya Hospital, Central South University, Changsha 410008, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Aug 28;49(8):1316-1326. doi: 10.11817/j.issn.1672-7347.2024.240187.
Immunotherapy has led to groundbreaking advances in anti-tumor treatment, yet significant clinical challenges remain such as the low proportion of beneficiaries and the lack of effective platforms for predicting therapeutic response. Organoid technology provides a novel solution to these issues. Organoids are three-dimensional tissue cultures derived from adult stem cells or pluripotent stem cells that closely replicate the structural and biological characteristics of native organs, demonstrating particularly strong potential in modeling the tumor microenvironment (TME). Tumor organoids can simulate TME effectively by retaining endogenous matrix components, including various immune cells, or by adding immune cells, cancer-associated fibroblasts, and other components. This provides a novel platform for predicting immunotherapy outcomes, evaluating adoptive cell therapies, and selecting personalized treatment options for patients. Summarizing strategies for constructing tumor organoids that simulate the microenvironment and understanding their advancements in immunotherapy research and clinical application can provide new insights for the development of tumor immunotherapy.
免疫疗法已在抗肿瘤治疗方面取得了突破性进展，但仍存在重大临床挑战，如受益患者比例低以及缺乏预测治疗反应的有效平台。类器官技术为这些问题提供了一种新的解决方案。类器官是源自成体干细胞或多能干细胞的三维组织培养物，它们紧密复制天然器官的结构和生物学特征，在模拟肿瘤微环境（TME）方面显示出特别强大的潜力。肿瘤类器官可以通过保留内源性基质成分（包括各种免疫细胞）或添加免疫细胞、癌症相关成纤维细胞和其他成分来有效模拟TME。这为预测免疫治疗结果、评估过继性细胞疗法以及为患者选择个性化治疗方案提供了一个新的平台。总结构建模拟微环境的肿瘤类器官的策略，并了解它们在免疫治疗研究和临床应用中的进展，可以为肿瘤免疫治疗的发展提供新的见解。
